Trial · NCT03686397
SVT-15652 Otic Solution for the Treatment of Otomycosis.
NCT03686397, Phase 3, Completed, Salvat; results first posted 2022-12-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SVT-15652 Otic Solution for the Treatment of Otomycosis. Trials, record NCT03686397. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03686397
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SVT-15652 Otic Solution for the Treatment of Otomycosis.
- NCT number
- NCT03686397
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 194 participants, actual
- Lead sponsor
- Salvat
- Conditions
- Otomycosis
- Interventions
- SVT-15652, Placebo
- First posted
- 2018-09-26
- Last updated
- 2022-12-15
- Results first posted
- 2022-12-15
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Therapeutic Cure (Clinical and Mycological Cure) | Test of cure on day 24 | Percentage of subjects with therapeutic cure |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Therapeutic Cure (Clinical and Mycological Cure) | Test of cure on day 24 | MITT Population: Randomized patients who had positive baseline fungal culture for Aspergillus spp and/or Candida spp | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Therapeutic Cure (Clinical and Mycological Cure) | SVT-15652 | 59 | Participants | ||
| Therapeutic Cure (Clinical and Mycological Cure) | Placebo | 8 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | SVT-15652 | 75 | |
| Overall Study | STARTED | Placebo | 35 | |
| Overall Study | COMPLETED | SVT-15652 | 70 | |
| Overall Study | COMPLETED | Placebo | 27 | |
| Overall Study | NOT COMPLETED | SVT-15652 | 5 | |
| Overall Study | NOT COMPLETED | Placebo | 8 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dizziness | Nervous system disorders | SVT-15652 | 0 | 127 | 0 |
| other | Dizziness | Nervous system disorders | Placebo | 3 | 64 | 3 |
| serious | Labyrinthitis | Infections and infestations | SVT-15652 | 0 | 127 | 0 |
| serious | Labyrinthitis | Infections and infestations | Placebo | 1 | 64 | 1 |
| serious | Cholesteatoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | SVT-15652 | 0 | 127 | 0 |
| serious | Cholesteatoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 1 | 64 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | SVT-15652 | 0 | 127 |
| Total, all-cause mortality | Placebo | 0 | 64 |
| Total, other adverse events | SVT-15652 | 0 | 127 |
| Total, other adverse events | Placebo | 3 | 64 |
| Total, serious adverse events | SVT-15652 | 0 | 127 |
| Total, serious adverse events | Placebo | 1 | 64 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| SVT-15652 vs Placebo: Therapeutic Cure (Clinical and Mycological Cure) | Trial comparisons |
| SVT-15652 vs Placebo: deaths from any cause | Trial comparisons |
| SVT-15652 vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03686397
GET https://conductscience.org/api/trials/v1/NCT03686397/registered